Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Aterognesis
Inflamacin
(1990s) Vulnerabilidad de la Placa
Recurrencia de EVA
(Indicadores no
invasivos)
PCR
Mantovani et al. Pentraxins in Innate Immunity: From C-Reactive
Protein to the Long Pentraxin PTX3. J Clin Immunol (2008) 28:113.
Rader, DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343:1179.
Asociacin significativa con prevalencia de EVA subyacente,
recurrencia de EVA, incidencia de nuevos eventos de EVA
Poca especifidad,
sin embargo
Pearson, TA, Mensah, GA, Alexander, RW, et al. Markers of inflammation and cardiovascular disease:
application to clinical and public health practice: A statement for healthcare professionals from the Centers
for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.
Aterognesis
Inflamacin
(1990s) Vulnerabilidad de la Placa
Marcador inflamatorio
PCR ?
Participante directo en la
progresin de la EVA
Podra promover un estado
proinflamatorio/ proaterosclertico
Heribert Schunkert, M.D., and Nilesh J. Samani, M.D., F.Med.Sci. Elevated C-Reactive Protein in
Atherosclerosis Chicken or Egg?. N Engl J Med 2008; 359:1953-1955 .
Marcador Inflamatorio
y de Riesgo Cardiovascular
Definiciones
Mtodo tradicional Umbral de 3-5 mg/L
Pearson, TA, Mensah, GA, Alexander, RW, et al. Markers of inflammation and cardiovascular disease:
application to clinical and public health practice: A statement for healthcare professionals from the Centers
for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.
Variabilidad
Edad Hipertensin
Lp(a)
IMC PCR
Dislipemia Diabetes tipo 2
Ridker et al. C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate
Risk: Moving an Inflammatory Hypothesis Toward Consensus. J Am Coll Cardiol. 2007 May 29;49(21):2129-38.
Evidencia: A favor
Comparando el tercio superior e inferior de cifras de PCRas, se observa
un RR 2 (IC 95% 1.6-2.5) para padecer eventos coronarios mayores
Estudio CC con 2500 casos y 4000 controles con un seguimiento medio de 18a,
OR ajustado fue de 1.45 para ECC. Casos = IM o Muerte por ECC.
Sin embargo, OR menor que el encontrado para CT, Tab, TA.
>2 vs. <0.78 mg/L. Danesh, J et al.N Engl J Med 2004; 350:1387. Islandia.
Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165:2063.
An assessment of incremental coronary risk prediction using C-reactive protein and other novel
risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006; 166:1368.
Score de Reynolds
Ridker et al. C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate
Risk: Moving an Inflammatory Hypothesis Toward Consensus. J Am Coll Cardiol. 2007 May 29;49(21):2129-38.
Es la PCR un predictor de aterosclerosis subclnica?
Toma de Tiempo a
muestra: Eventos:
Al ingreso 14 das
n = 437
CABG
Toma de muestra: Seguimiento
Preoperatoria 3.6 aos
n = 86
< 3 mg/L > 3 mg/L
4% 25%
Milazzo et al. Elevated levels of C-reactive protein before coronary artery bypass
grafting predict recurrence of ischemic events. Am J Cardiol 1999; 84:459.
Riesgo post-PCI
Angina E/I
Toma de muestra: Seguimiento:
Preprocedimiento 1 ao
n = 121
PTCA
0% 22%
Complicaciones
intrahospitalarias
Buffon et al. Preprocedural serum levels of C-reactive protein predict early complications and
late restenosis after coronary angioplasty. J Am Coll Cardiol 1999 Nov 1;34(5):1512-21.
Otras asociaciones con la
PCR
ICC, ICC-D, Mx (HR 1.53)
HTA
Mecanismos Fisiopatolgicos
Se fija a fosfocolina
Monocitos en
sangre perifrica.
La act. procoagulante de la
PCR se bloquea con Ac anti FT
PCR
SAP
FcGammaR-IIA
Representacin de la unin de una pentraxina (SAP) con el
receptor de baja afinidad de inmunoglobulinas FcGammaR-IIA
Publicado el 11-11-08 en EEUU por Lu et al. Difraccin de Rayos X
FcGammaR-IIA
SAP
Representacin de la unin de una pentraxina (SAP) con el
receptor de baja afinidad de inmunoglobulinas FcGammaR-IIA
Publicado el 11-11-08 en EEUU por Lu et al. Difraccin de Rayos X
SAP FcGammaR-IIA
Interviniente en la Fisiopatologa
de la Enfermedad
Aterosclertica
A favor
2 mg/kg SC/sem de PCR nativa por 8 sem SF
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in
apolipoprotein E-knockout mice. Schwedler et al. Circulation 2005 Aug 16;112(7):1016-23.
Division of Nephrology, Department of Medicine, University of Wurzburg, Wurzburg, Germany.
A favor
PCRh IV iPCRh + PCRh IV
1,6-bis(fosfocolina)-hexano
C-reactive protein and complement are important mediators of tissue damage in acute
myocardial infarction. Griselli M et al. J Exp Med 1999 Dec 20;190(12):1733-40.
Department of Histopathology, Hammersmith Hospital, London, United Kingdom.
En contra
n = 125 Seguimiento:
Pcts con ECV sin DM 12 semanas
PCRas 1-10 mg/L
Disminuye expresin
de IL-6 y TNFalfa
Disminuye la
transcripcin
del gen CRP
PCR y Estatinas
PCR en 13 a 50%
Ridker et al. C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate
Risk: Moving an Inflammatory Hypothesis Toward Consensus. J Am Coll Cardiol. 2007 May 29;49(21):2129-38.
JUPITER n = 17802
Seguimiento:
1.9 aos
Rosuvastatina 20 mg/d
EVA: 0.77 por cada 100 EVA: 1.36 por cada 100
Ridker et al. Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER). Rosuvastatin to prevent vascular events in men and women with
elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207.
JUPITER
Ridker et al. Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER). Rosuvastatin to prevent vascular events in men and women with
elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207.
Conclusiones
Prevencin Primaria:
Prevencin Secundaria:
Futuro:
La aplicacin de tratamientos para contrarestar
los efectos fisiopatolgicos de la PCR en los SCA,
resulta un campo fascinante, que podra iniciar
una nueva era en la cardioproteccin.
Secuencia